Medico Remedies

Why is Medico Remedies Ltd falling/rising?

As of 16-Jun, Medico Remedies Ltd's stock price is at Rs 42.11, reflecting a year-to-date decline of 16.71%. The stock is underperforming against the benchmark Sensex and shows negative trends in longer-term moving averages, alongside decreased investor participation.

As of 16-Jun, Medico Remedies Ltd's stock price is experiencing a slight decline, currently at Rs 42.11, down by Rs 0.09 or 0.21%. This decrease is reflected in the stock's performance over various periods, showing a significant year-to-date decline of 16.71%, compared to a 9.87% drop in the benchmark Sensex. Over the past week and month, the stock has also underperformed, with declines of 3.24% and 4.21%, respectively.<BR><BR>Despite today's performance indicating that the stock outperformed its sector by 2.4% and reached an intraday high of Rs 43.92, the overall trend remains negative. The stock's moving averages indicate that while it is higher than the 5-day and 50-day moving averages, it is lower than the 20-day, 100-day, and 200-day moving averages, suggesting a bearish trend in the longer term.<BR><BR>Additionally, there has been a notable decline in investor participation, with delivery volume falling by 11.75% against the 5-day average. This decrease in trading activity may contribute to the stock's downward pressure. Overall, the combination of poor performance relative to the benchmark, declining investor interest, and negative trends in longer-term moving averages are key factors contributing to the stock's current decline.

Which are the latest news on Medico Remedies?

Should I buy, sell or hold Medico Remedies Ltd?

What does Medico Remedies do?

Medico Remedies Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, incorporated in 1994 and publicly listed since 2017, with recent net sales of 57 Cr and net profit of 6 Cr as of March 2026. Key financial metrics include a P/E ratio of 28.00 and a market cap of INR 360 Cr.

Overview: <BR>Medico Remedies Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>Medico Remedies Limited was incorporated in 1994 as a Private Limited Company and later changed its status to a Public Limited Company in 2017. The most recent quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 57 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 6 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 360 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 28.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.16 <BR>Return on Equity: 19.62% <BR>Price to Book: 5.43<BR><BR>Contact Details: <BR>Address: 1105/1106 11-Flr Hubtown Solar, N S Phadke Marg Andheri East Mumbai Maharashtra : 400069 <BR>Tel: 91-22-2670 1055/66 <BR>Email: info@medicoremedies.com <BR>Website: http://www.medicoremedies.com

How big is Medico Remedies?

As of 10th June, Medico Remedies Ltd has a market capitalization of 360.00 Cr, with recent net sales of 206.38 Cr and a net profit of 13.12 Cr. The balance sheet for March 2025 shows shareholder's funds of 62.47 Cr and total assets of 119.55 Cr.

As of 10th June, Medico Remedies Ltd has a market capitalization of 360.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Medico Remedies reported Net Sales of 206.38 Cr and a Net Profit of 13.12 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing Shareholder's Funds of 62.47 Cr and Total Assets of 119.55 Cr.

Who are in the management team of Medico Remedies?

The management team of Medico Remedies includes Haresh Mehta (Chairman & Wholetime Director), Harshit Mehta (Managing Director), Rita Mehta (Director), Rishit Mehta (Whole-time Director), and several independent directors: Deepak Vekaria, Ramesh Rughani, Bharat Rathod, and Deepesh Shah, along with Dinesh Modi as Company Secretary & Compliance Officer. They oversee the company's operations and strategic direction.

The management team of Medico Remedies includes the following individuals:<BR><BR>1. **Haresh Mehta** - Chairman & Wholetime Director<BR>2. **Harshit Mehta** - Managing Director<BR>3. **Rita Mehta** - Director<BR>4. **Rishit Mehta** - Whole-time Director<BR>5. **Deepak Vekaria** - Independent Director<BR>6. **Ramesh Rughani** - Independent Director<BR>7. **Bharat Rathod** - Independent Director<BR>8. **Dinesh Modi** - Company Secretary & Compliance Officer<BR>9. **Deepesh Shah** - Independent Director<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

Who are the peers of the Medico Remedies?

Peers of Medico Remedies include Albert David, Valiant Laborato, Bafna Pharma, Transchem, Medicamen Biotec, Trident Lifeline, Zenotech Lab, Ambalal Sarabhai, and Infinium Pharma. Key insights show varying management risks, growth rates, and capital structures among these companies, with Bafna Pharma leading in 1-year returns at 135.40% and Medicamen Biotec at -46.53%.

Peers: The peers of Medico Remedies are Albert David, Valiant Laborato, Bafna Pharma., Transchem, Medicamen Biotec, Trident Lifeline, Zenotech Lab., Ambalal Sarabhai, and Infinium Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Albert David and Medicamen Biotec, while Average management risk is found at Transchem, Trident Lifeline, Zenotech Lab., and the rest. Below Average management risk is present at Valiant Laborato, Bafna Pharma., Ambalal Sarabhai, and Infinium Pharma. Growth is rated as Good for Valiant Laborato and Zenotech Lab., while Average growth is seen at Ambalal Sarabhai, and the rest show Below Average growth. Excellent capital structure is noted for Albert David and Medicamen Biotec, while Good capital structure is found at Medico Remedies, Trident Lifeline, and the rest, with Below Average capital structure at Valiant Laborato, Transchem, and Bafna Pharma.<BR><BR>Return Snapshot: Bafna Pharma. has the highest 1-year return at 135.40%, while Medicamen Biotec has the lowest at -46.53%. Medico Remedies' 1-year return is -10.34%, which is higher than Medicamen Biotec but lower than Bafna Pharma. Additionally, peers with negative six-month returns include Medicamen Biotec and Zenotech Lab.

Are Medico Remedies Ltd latest results good or bad?

Medico Remedies Ltd's latest results show strong year-on-year growth with record net sales and profit, but a 3.19% revenue decline from the previous quarter and reduced operating margins raise concerns about stability. Investors should consider both the impressive growth and the potential volatility in performance.

Medico Remedies Ltd's latest results present a mixed picture. On the positive side, the company achieved record quarterly net sales of ₹56.81 crores, reflecting a strong year-on-year growth of 37.55%. Additionally, net profit surged to ₹5.86 crores, marking a significant 35.02% increase compared to the same quarter last year. This demonstrates impressive momentum in terms of revenue and profitability.<BR><BR>However, there are concerns regarding sequential performance. Revenue declined by 3.19% from the previous quarter, and operating margins contracted to 12.59%, down from 16.15% a year ago. This volatility in margins raises questions about the company's ability to maintain consistent performance. Furthermore, a notable portion of the profit came from non-operating income, which constituted 34.50% of profit before tax, indicating a reliance on sources outside of core operations.<BR><BR>Overall, while the year-on-year growth figures are strong, the sequential decline in revenue and margin volatility suggest that the company's performance is not entirely stable. Investors should weigh these factors carefully when assessing the company's outlook.

When is the next results date for Medico Remedies Ltd?

The next results date for Medico Remedies Ltd is 12 February 2026.

The next results date for Medico Remedies Ltd is scheduled for 12 February 2026.

How has been the historical performance of Medico Remedies?

Medico Remedies has shown consistent growth in net sales and profits, with net sales increasing from 121.02 Cr in Mar'22 to 150.94 Cr in Mar'25, and operating profit rising from 7.21 Cr to 15.00 Cr during the same period. The company's total assets also expanded significantly, reflecting a robust financial performance.

Answer:<BR>The historical performance of Medico Remedies shows a consistent growth trend in net sales and profits over the years, with significant improvements in various financial metrics.<BR><BR>Breakdown:<BR>Medico Remedies has demonstrated a steady increase in net sales, rising from 121.02 Cr in Mar'22 to 150.94 Cr in Mar'25. This growth is reflected in total operating income, which also increased from 121.02 Cr in Mar'22 to 150.94 Cr in Mar'25. The raw material cost has similarly risen, from 84.67 Cr in Mar'22 to 111.39 Cr in Mar'25, while total expenditure has grown from 113.81 Cr in Mar'22 to 135.94 Cr in Mar'25. Operating profit, excluding other income, has improved significantly from 7.21 Cr in Mar'22 to 15.00 Cr in Mar'25, contributing to an operating profit margin that increased from 5.96% to 9.94% over the same period. Profit before tax has also shown a positive trend, climbing from 6.55 Cr in Mar'22 to 13.50 Cr in Mar'25, with profit after tax following suit from 4.89 Cr to 10.09 Cr. The company's total assets have expanded from 77.22 Cr in Mar'22 to 119.55 Cr in Mar'25, while total liabilities have increased from 77.22 Cr to 119.55 Cr during the same timeframe. Cash flow from operating activities has fluctuated, showing a cash inflow of 2.00 Cr in Mar'24 after a previous high of 8.00 Cr in Mar'23. Overall, Medico Remedies has shown a robust financial performance with increasing revenues and profits, alongside a growing asset base.

Is Medico Remedies overvalued or undervalued?

As of November 27, 2025, Medico Remedies is considered overvalued with a PE ratio of 37.29, a Price to Book Value of 6.33, and an EV to EBITDA of 28.31, indicating high valuations relative to earnings and assets, despite having a lower PE than Sun Pharma and a higher PEG ratio of 0.78 compared to its peers.

As of 27 November 2025, Medico Remedies has moved from a fair to an expensive valuation grade. The company appears overvalued based on its current financial metrics. The PE ratio stands at 37.29, while the Price to Book Value is 6.33, and the EV to EBITDA is 28.31, indicating a high valuation relative to its earnings and assets.<BR><BR>In comparison to its peers, Medico Remedies' PE ratio is slightly lower than Sun Pharma's 37.62 but significantly higher than Cipla's attractive PE of 22.67. Additionally, the PEG ratio of 0.78 suggests that while the company may have growth potential, its current price does not reflect a favorable valuation compared to its earnings growth. Recent stock performance shows that while Medico Remedies has outperformed the Sensex over the past year, it has lagged behind in the year-to-date comparison, reinforcing the notion that the stock may be overvalued at this time.

What is the technical trend for Medico Remedies?

As of June 2, 2025, Medico Remedies is in a bearish trend with moderate strength, driven by bearish signals from key indicators like the MACD, Bollinger Bands, and moving averages, despite some bullish signals from the OBV.

As of 2 June 2025, the technical trend for Medico Remedies has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this assessment include the weekly MACD and Bollinger Bands both signaling bearish trends, alongside daily moving averages also indicating bearish momentum. The KST is bearish on a weekly basis and mildly bearish on a monthly basis, while the Dow Theory reflects a mildly bearish stance on the weekly and monthly charts. Despite the OBV showing bullish signals on both weekly and monthly time frames, the overall technical picture remains bearish.

Who are the top shareholders of the Medico Remedies?

The top shareholders of Medico Remedies include Haresh Kapurlal Mehta with 20.76%, followed by public shareholder Ravi Goyal Huf at 6.84%. Individual investors hold a combined 22.13%, and there are no pledged promoter holdings.

The top shareholders of Medico Remedies include the promoters, with Haresh Kapurlal Mehta holding the highest stake at 20.76%. Additionally, the highest public shareholder is Ravi Goyal Huf, who owns 6.84%. The company also has individual investors holding a combined 22.13%. There are no pledged promoter holdings, and the company is held by six foreign institutional investors, accounting for 0.12%.

What is the bonus history of the Medico Remedies?

Medico Remedies issued a significant bonus in a 3:1 ratio, with an ex-date of November 16, 2021, and a record date of November 17, 2021, meaning shareholders received three additional shares for each share held.

Medico Remedies has a bonus history that includes a significant bonus issue announced as a 3:1 ratio. This bonus was issued with an ex-date of November 16, 2021, and the record date was November 17, 2021. This means that for every one share held, shareholders received three additional shares. If you have any more questions about Medico Remedies or need further details, feel free to ask!

Has Medico Remedies declared dividend?

No Dividend History Available